Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections.
Xellia Pharmaceuticals (Xellia) is and intends to remain a main player in the global supply of life-saving antibiotics. In order to obtain this, Xellia Pharmaceutical’s API R&D focus has been, is and will remain to develop cost-efficient manufacturing processes for new antibiotics and to constantly improve existing manufacturing processes. Within this scope, SFI-IB is a perfect fit to ensure better and even more efficient future manufacturing processes for these crucial antibiotics.
SFI-IB will enable prudent focus and structured efforts to establish new technology for high throughput screening and improved methodology/ efficient ways of developing high producing bacterial strains to combat life-threatening infections. The cluster of industrial partners and the involved research institutions will provide new opportunities for synergies and novel approaches..
Xellia Pharmaceuticals is an industry partner in the project.
2300 Copenhagen S Denmark